Hims & Hers Health (HIMS): Navigating GLP-1 Transition Amid Margin Pressures and Raised Guidance
Key Takeaways
- Hims & Hers Health reported Q1 2026 revenue of $608.1 million, up 4% year-over-year but missing estimates, with a surprise net loss of $92.1 million due to higher costs from shifting to branded GLP-1 (glucagon-like peptide-1) weight-loss drugs.
- Shares dropped over 14% post-earnings amid margin pressure, though the company raised full-year 2026 revenue guidance to $2.8–$3.0 billion.
- Strategic partnerships with Novo Nordisk and Eli Lilly for branded GLP-1 offerings reduce regulatory risks but introduce short-term profitability challenges.
- Analyst consensus holds a "Hold" rating with an average price target around $30–$32, reflecting mixed views on growth versus near-term headwinds.
- Subscriber base reached nearly 2.6 million, up 9% year-over-year, signaling sustained demand in personalized telehealth.
A Quick Look at HIMS in the Current Market
I've been following Hims & Hers Health (HIMS) closely through recent sessions, and the stock's volatility stands out amid reactions to its earnings and shifts in the weight-loss segment. Shares have pulled back from earlier highs due to worries about margins during the move from compounded to branded GLP-1 therapies. That said, strong subscriber growth and lifted full-year revenue forecasts point to solid demand for the telehealth platform across sexual health, dermatology, and mental health. From what I see, market sentiment is holding steady, with focus on how partnerships and international moves play out in this cycle.
Recent Moves Shaping HIMS Stock Performance
In my analysis of HIMS, the aggressive shift in weight-loss offerings has driven much of the recent turbulence. The Q1 2026 earnings on May 11 showed revenue at $608.1 million—up 4% year-over-year but short of the $616.85 million expected—and a net loss of $92.1 million versus prior profits. Adjusted EBITDA dropped to $44 million from $91 million last year. I also checked this using Tickeron’s AI Screener to gauge how it stacks up against peers. These misses, tied to costs from branded GLP-1 drugs like Novo Nordisk's Wegovy, led to a 14% drop the next day, sending shares toward the low $20s.
Before earnings, the stock had climbed on key announcements. Early April brought renewed ties with Novo Nordisk and Eli Lilly for FDA-approved GLP-1 meds, easing risks from compounded semaglutide under FDA watch. Needham upped its target to $35, pointing to over 100,000 monthly weight-loss subs. J.P. Morgan started "Overweight" coverage at $35, noting lower regulatory hurdles. This sparked a rally toward $30.
Competition heated up, though, with Amazon's GLP-1 push via One Medical weighing on sentiment and causing dips. The $1.15 billion Eucalyptus deal for Australia, Japan, and Europe adds upside but integration expenses. After earnings, views split: Needham and Canaccord raised to $35 and $32 on growth, while Jefferies cut to $24.50 and BofA to $30 over guidance. Consensus stays "Hold" at $31.86 average.
Subscribers hit 2.6 million, up 9%, but revenue per user fell to $80 from $85 on mix changes. FY2026 guidance rose to $2.8–$3.0 billion (from $2.7–$2.9 billion), Q2 to $680–$700 million, yet margin issues fueled the selloff. Price action ties straight to GLP-1 changes: partnership buzz lifted shares early, execution costs revealed risks, within a 52-week range of $13.74–$70.43.
Exploring Tickeron's Trending AI Robots
One tool I rely on for insights into volatile markets like this is Tickeron’s Trending AI Robots. This page highlights top-performing AI trading bots from hundreds of agents scanning thousands of tickers. They use strategies like pattern recognition and trend-following on 5-60 minute frames or longer momentum, posting annualized returns up to 171%, win rates of 68–95%, and profit factors over 4.0 in areas like semiconductors, aerospace, and energy. Only bots beating benchmarks with strong risk-adjusted stats—such as 100% profitable trades in some 30-day stretches or 83% success—make the cut. It's a practical way to spot high-conviction plays amid current swings; I check it regularly to refine my approach.
Looking Ahead to 2026: What Matters Most
One thing that stands out for HIMS in 2026 is executing the branded GLP-1 plan, with Novo Nordisk and Eli Lilly partnerships tapping a $100 billion weight-loss market despite FDA peptide shifts. Retention over 85% and Hers brand revenue possibly topping $1 billion underscore AI-personalized care in menopause, testosterone, and diagnostics. Eucalyptus should boost international revenue, backing $2.8–$3.0 billion guidance.
Risks persist with margin strain from pricier drugs—adjusted EBITDA at $275–$350 million (10–12% margin)—plus Amazon and pharma rivalry. Optimizing labs and at-home devices is key for scale. Long-term 2030 goals of $6.5 billion revenue and $1.3 billion EBITDA hinge on ecosystem growth and precision medicine. I'll be tracking subscriber adds, GLP-1 ramps, and regs quarterly in telehealth's shift.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
HIMS's Stochastic Oscillator is sitting in oversold zone for 2 days
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HIMS advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 264 cases where HIMS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for HIMS moved out of overbought territory on July 07, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HIMS as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for HIMS turned negative on July 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIMS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
HIMS broke above its upper Bollinger Band on June 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. HIMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.978) is normal, around the industry mean (46.654). P/E Ratio (57.137) is within average values for comparable stocks, (99.739). Projected Growth (PEG Ratio) (2.155) is also within normal values, averaging (1.668). HIMS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.035). P/S Ratio (3.504) is also within normal values, averaging (114.968).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which is involved in real estate investment trusts
Industry PharmaceuticalsGeneric
Advertisement